ArticleJournal of advanced pharmaceutical technology & research
Protective effect of fermented vegetable compounds against nonalcoholic fatty liver disease using metabolite profiling, integrated network pharmacology, and molecular docking approach.
Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vegetable fermentation extract (VFE) shows potential as a preventive agent to inhibit nonalcoholic fatty liver disease (NAFLD). This study identified bioactive compounds of VFE and explored the mechanism of VFE against NAFLD. Metabolite profiling was analysed using Liquid chromatography-tandem mass spectrometry (LC-MS/MS). The bioactive compounds were screened using the Lipinski Rule of 5, toxicity, and biological activity prediction, followed by network pharmacology and molecular docking. Of the 24 bioactive compounds identified, 8 compounds passed the screening process. Twenty-four genes from network pharmacology were involved in the NAFLD mechanism, including those related to insulin signaling, inflammation, and lipid metabolism. Kaempferol, apigenin, and N-(p-coumaroyl) serotonin showed a good binding affinity with CCR2, AKT, IL-6, and PPAR-γ compared to simvastatin and metformin. Bioactive compounds from VFE were predicted to ameliorate NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.